Cushing’s syndrome – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:13:41 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Cushing’s syndrome – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on the Long-Term Safety of Relacorilant for Patients with Cushing Syndrome https://clinicaltrials.eu/trial/study-on-the-long-term-safety-of-relacorilant-for-patients-with-cushing-syndrome/ Mon, 04 May 2026 08:00:37 +0000 https://clinicaltrials.eu/trial/study-on-the-long-term-safety-of-relacorilant-for-patients-with-cushing-syndrome/ This clinical trial is focused on studying the long-term safety of a treatment for Endogenous Cushing Syndrome, a condition where the body produces too much of the hormone cortisol. The treatment being studied is a medication called relacorilant, also known by its code name CORT125134. This study is an extension of previous research to further understand how safe relacorilant is for patients with this condition.

The purpose of the study is to monitor the safety of relacorilant over an extended period. Participants in the study will continue to receive relacorilant and will be regularly assessed for any side effects or changes in their health. This includes checking for any new or worsening symptoms, as well as conducting routine health checks such as blood tests, physical exams, and heart monitoring using electrocardiograms (ECGs). For those with a specific type of Cushing Syndrome caused by a pituitary tumor, magnetic resonance imaging (MRI) scans will be used to observe any changes in the tumor.

Throughout the study, participants will have regular visits to the study site to ensure their well-being and to gather important information about the effects of relacorilant. The study aims to provide valuable insights into the long-term use of relacorilant for managing the symptoms of Endogenous Cushing Syndrome, helping to improve treatment options for those affected by this condition.

]]> Study on Fluasterone for Managing High Blood Sugar in Adults with Cushing’s Syndrome https://clinicaltrials.eu/trial/study-on-fluasterone-for-managing-high-blood-sugar-in-adults-with-cushings-syndrome/ Wed, 29 Apr 2026 14:30:42 +0000 https://clinicaltrials.eu/trial/study-on-fluasterone-for-managing-high-blood-sugar-in-adults-with-cushings-syndrome/ This clinical trial is focused on studying Cushing’s syndrome, a condition where the body produces too much of the hormone cortisol, leading to various health issues, including high blood sugar levels. The study will test the effectiveness and safety of a new treatment called Fluasterone Buccal Tablet. This medication is designed to be taken by placing it against the inside of the cheek, allowing it to dissolve and enter the bloodstream. The trial will also use placebo buccal tablets for comparison.

The purpose of the study is to determine how well the Fluasterone Buccal Tablet can control high blood sugar levels in adults with Cushing’s syndrome. Participants will be involved in a double-blind, placebo-controlled, crossover study, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo at any given time. The study will last for a total of 12 weeks, during which participants will receive both the medication and the placebo at different times.

Throughout the study, participants will have their blood sugar levels monitored, and other health indicators will be assessed to ensure the treatment’s safety and effectiveness. The trial aims to provide valuable information on whether the Fluasterone Buccal Tablet can be a beneficial treatment option for managing high blood sugar in people with Cushing’s syndrome.

]]> CSRF https://clinicaltrials.eu/organisation/csrf/ Wed, 29 Apr 2026 13:34:17 +0000 https://clinicaltrials.eu/organisation/csrf/ The Cushing’s Support & Research Foundation (CSRF) serves as a comprehensive resource and support hub for individuals affected by Cushing’s disease, a rare endocrine disorder. Key offerings include practical guidance on navigating social security disability benefits and securing financial and travel assistance.

]]>